These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 8943677)
41. Treatment of advanced gastric cancer with the combination fluorouracil, leucovorin, etoposide, and cisplatin: a phase II study of the ONCOPAZ Cooperative Group. González-Barón M; Feliu J; Espinosa E; García-Girón C; Chacón I; Garrido P; Colmenarejo A; Ordóñez A; Zamora P Cancer Chemother Pharmacol; 1995; 36(3):255-8. PubMed ID: 7781148 [TBL] [Abstract][Full Text] [Related]
42. A phase II study of irinotecan with biweekly, low dose leucovorin and bolus and continuous infusion 5-fluorouracil (modified FOLFIRI) as first line therapy for patients with recurrent or metastatic gastric cancer. Kim BG; Oh SY; Kwon HC; Lee S; Lee DM; Kim SG; Kim DK; Jang JS; Kim MC; Kim SH; Kim HJ Am J Clin Oncol; 2010 Jun; 33(3):246-50. PubMed ID: 19770628 [TBL] [Abstract][Full Text] [Related]
43. Cisplatin, etoposide, and weekly high-dose 5-fluorouracil and leucovorin infusion (PE-HDFL)--a very effective regimen with good patients' compliance for advanced gastric cancer. Cheng AL; Yeh KH; Lin JT; Hsu C; Liu MY Anticancer Res; 1998; 18(2B):1267-72. PubMed ID: 9615799 [TBL] [Abstract][Full Text] [Related]
44. Induction with mitomycin C, doxorubicin, cisplatin and maintenance with weekly 5-fluorouracil, leucovorin for treatment of metastatic nasopharyngeal carcinoma: a phase II study. Hong RL; Sheen TS; Ko JY; Hsu MM; Wang CC; Ting LL Br J Cancer; 1999 Aug; 80(12):1962-7. PubMed ID: 10471046 [TBL] [Abstract][Full Text] [Related]
45. Weekly infusional high-dose fluorouracil (HD-FU), HD-FU plus folinic acid (HD-FU/FA), or HD-FU/FA plus biweekly cisplatin in advanced gastric cancer: randomized phase II trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie. Lutz MP; Wilke H; Wagener DJ; Vanhoefer U; Jeziorski K; Hegewisch-Becker S; Balleisen L; Joossens E; Jansen RL; Debois M; Bethe U; Praet M; Wils J; Van Cutsem E; ; J Clin Oncol; 2007 Jun; 25(18):2580-5. PubMed ID: 17577037 [TBL] [Abstract][Full Text] [Related]
46. A phase III randomized study of 5-fluorouracil and cisplatin versus 5-fluorouracil, doxorubicin, and mitomycin C versus 5-fluorouracil alone in the treatment of advanced gastric cancer. Kim NK; Park YS; Heo DS; Suh C; Kim SY; Park KC; Kang YK; Shin DB; Kim HT; Kim HJ Cancer; 1993 Jun; 71(12):3813-8. PubMed ID: 8508349 [TBL] [Abstract][Full Text] [Related]
47. Infusional 5-FU, folinic acid, paclitaxel, and cisplatin for metastatic breast cancer. Klaassen U; Wilke H; Müller C; Borquez D; Korn M; Achterrath W; Harstrick A; Diergarten K; Seeber S Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):38-40. PubMed ID: 9144690 [TBL] [Abstract][Full Text] [Related]
48. Treatment outcomes of oxaliplatin, 5-FU, and leucovorin as salvage therapy for patients with advanced or metastatic gastric cancer: a retrospective analysis. Seo HY; Kim DS; Choi YS; Sung HJ; Park KH; Choi IK; Kim SJ; Oh SC; Seo JH; Choi CW; Kim BS; Shin SW; Kim YH; Kim JS Cancer Chemother Pharmacol; 2009 Feb; 63(3):433-9. PubMed ID: 18398608 [TBL] [Abstract][Full Text] [Related]
49. [Docetaxel-cisplatin-5-FU combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric cancer]. Kang SH; Kim JI; Goh PG; Hwang SW; Kwon DS; Nam KW; Kang HM; Kang YS; Moon HS; Kim SH; Seong JK; Lee BS; Jeong HY Korean J Gastroenterol; 2007 Sep; 50(3):157-63; discussion 207-9. PubMed ID: 17885280 [TBL] [Abstract][Full Text] [Related]
50. Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer. Ustaalioglu BBO; Bilici A; Tilki M; Surmelioglu A; Erkol B; Figen M; Uyar S J Cancer Res Ther; 2018 Sep; 14(Supplement):S736-S741. PubMed ID: 30249896 [TBL] [Abstract][Full Text] [Related]
51. Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer. Kim JA; Lee J; Han B; Park SH; Park JO; Park YS; Lim HY; Kang WK Cancer Chemother Pharmacol; 2011 Jul; 68(1):177-84. PubMed ID: 20878159 [TBL] [Abstract][Full Text] [Related]
52. Phase I/II study of irinotecan, 5-fluorouracil, and l-leucovorin combination therapy (modified Saltz regimen) in patients with metastatic colorectal cancer. Goto A; Yamada Y; Hosokawa A; Ura T; Arai T; Hamaguchi T; Muro K; Shimada Y; Shirao K Int J Clin Oncol; 2004 Oct; 9(5):364-8. PubMed ID: 15549585 [TBL] [Abstract][Full Text] [Related]
53. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. Vokes EE; Choi KE; Schilsky RL; Moran WJ; Guarnieri CM; Weichselbaum RR; Panje WR J Clin Oncol; 1988 Apr; 6(4):618-26. PubMed ID: 3258629 [TBL] [Abstract][Full Text] [Related]
54. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma. Uncu D; Ozdemir NY; Aksoy S; Abali H; Oksuzoglu BC; Budakoglu B; Yildiz R; Aslan N; Zengin N Asian Pac J Cancer Prev; 2010; 11(6):1493-7. PubMed ID: 21338186 [TBL] [Abstract][Full Text] [Related]
55. [Evaluation of the efficacy and toxicity of protocol cisplatin, 5-fluorouracil, leucovorin compared to protocol fluorouracil, doxorubicin and mitomycin C in locally advanced and metastatic gastric cancer]. Andrić Z; Randjelović T; Kovčin V; Gutović J; Crevar S; Murtezani Z; Kostić S Srp Arh Celok Lek; 2012; 140(5-6):305-12. PubMed ID: 22826983 [TBL] [Abstract][Full Text] [Related]
56. Combination chemotherapy comprising 5-fluorouracil, leucovorin, etoposide, and cis-diamminedichloroplatinum for the treatment of advanced gastric cancer. Mochizuki F; Fujii M; Kasakura Y; Yamagata M; Kochi M; Wakabayashi K; Kanamori N; Takayama T J Cancer Res Clin Oncol; 2002 Sep; 128(9):493-6. PubMed ID: 12242513 [TBL] [Abstract][Full Text] [Related]
57. [Combination of 5-FU, high dose methotrexate, epirubicin and cisplatin (FEMTX-P protocol) in non surgical or locally recurrent metastatic gastric cancers]. Conroy T; Wils J; Paillot B; Wagener DJ; Burghouts JT; Fickers MM; de Graeff A; Lalisang FM Bull Cancer; 1993 Mar; 80(3):255-60. PubMed ID: 8173178 [TBL] [Abstract][Full Text] [Related]
58. Mitomycin C, 5-fluorouracil, leucovorin, and oxaliplatin as a salvage therapy for patients with cisplatin-resistant advanced gastric cancer: a phase I dose escalation trial. Al-Batran SE; Kerber A; Atmaca A; Dechow C; Reitsamer E; Schmidt S; Kolassa Y; Neumann A; Weidmann E; Hartmann JT; Jäger E Onkologie; 2007 Feb; 30(1-2):29-34. PubMed ID: 17264523 [TBL] [Abstract][Full Text] [Related]
59. [A case of advanced gastric cancer that responded to docetaxel with low-dose 5-FU and cisplatin combination chemotherapy after becoming chemoresistant to M-FLP]. Funakoshi K; Tasaki A; Inayoshi J; Arai F; Motoyama H; Akiyama N; Kato T Gan To Kagaku Ryoho; 2003 Nov; 30(12):1967-71. PubMed ID: 14650969 [TBL] [Abstract][Full Text] [Related]
60. Combination chemotherapy with capecitabine (X) and Cisplatin (P) as first line treatment in advanced gastric cancer: experience of 223 patients with prognostic factor analysis. Lee SS; Lee JL; Ryu MH; Chang HM; Kim TW; Kang HJ; Kim WK; Lee JS; Kang YK Jpn J Clin Oncol; 2007 Jan; 37(1):30-7. PubMed ID: 17272321 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]